采用下一代测序技术鉴定全基因组血清 microRNA 表达谱作为慢性肾脏病潜在的非侵入性生物标志物。
Identification of a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for chronic kidney disease using next-generation sequencing.
机构信息
Department of Nephrology, The Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Vascular Calcification in Kidney Disease, Hebei Clinical Research Center for Chronic Kidney Disease, Shijiazhuang, China.
Department of Hematology, The First Hospital of Hebei Medical University, Shijiazhuang, China.
出版信息
J Int Med Res. 2020 Dec;48(12):300060520969481. doi: 10.1177/0300060520969481.
OBJECTIVE
To identify serum microRNAs (miRNAs) as potential non-invasive biomarkers for patients with chronic kidney disease (CKD).
METHODS
We collected serum samples from healthy controls, CKD stage 1 (CKD1), and stage 5 (CKD5) patients with primary glomerulonephritis (GN), screened differentially expressed miRNAs (DEMs) using next-generation sequencing (NGS), and confirmed the sequencing data using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
RESULTS
We identified 20 and 42 DEMs in the CKD1 and CKD5 patients compared with the controls, respectively, and 70 DEMs in the CKD5 compared with the CKD1 patients. The qRT-PCR results showed that miR-483-5p was up-regulated in the CKD1 and CKD5 patients compared with controls (fold change = 2.56 and 18.77, respectively). miR-363-3p was down-regulated in the CKD5 patients compared with the controls and CKD1 patients (fold change = 0.27 and 0.48, respectively).
CONCLUSION
We identified a genome-wide serum miRNA expression profile in CKD patients, and serum miR-483-5p and miR-363-3p may act as potential diagnostic biomarkers for CKD.
目的
鉴定血清 microRNAs（miRNAs）作为慢性肾脏病（CKD）患者潜在的非侵入性生物标志物。
方法
我们收集了原发性肾小球肾炎（GN）的健康对照者、CKD1 期和 CKD5 期患者的血清样本，使用下一代测序（NGS）筛选差异表达的 miRNAs（DEMs），并使用定量逆转录聚合酶链反应（qRT-PCR）对测序数据进行了验证。
结果
与对照组相比，CKD1 期和 CKD5 期患者分别鉴定出 20 个和 42 个 DEMs，而 CKD5 期患者与 CKD1 期患者相比则鉴定出 70 个 DEMs。qRT-PCR 结果显示，与对照组相比，CKD1 期和 CKD5 期患者的 miR-483-5p 表达上调（倍数变化分别为 2.56 和 18.77）。与对照组和 CKD1 期患者相比，miR-363-3p 在 CKD5 期患者中下调（倍数变化分别为 0.27 和 0.48）。
结论
我们鉴定了 CKD 患者的全基因组血清 miRNA 表达谱，血清 miR-483-5p 和 miR-363-3p 可能作为 CKD 的潜在诊断生物标志物。
Zotero 插件